Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Marine liquid and fluids refers to an experimental biological treatment derived from the hemolymph and plasma of the freshwater bivalve *Anodonta cygnea*. Developed by the Universidade do Porto, this intervention is being evaluated for its potential to modulate the immune response in patients infected with SARS-CoV-2 (COVID-19) and other SARS-related viruses. The treatment protocol involves the extraction of bio-active composites from the bivalves under specific stress conditions, followed by the application of bioresonance frequencies using the Mora® Nova apparatus. This 'Intelligent Medicine Integration' approach aims to identify and utilize specific frequencies or components within the bivalve fluids to ameliorate symptoms and enhance the immune capacity of infected individuals. The therapy is currently in Phase 2 clinical testing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Marine liquid and fluids.